arrow
H

Hugo Luzardo

institut d'investigacio biomedica de bellvitge (idibell)
H指数:9
被引数:410

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Laboratory Prognostic Index (LAB-PI) in diffuse large B-cell lymphoma: a single blood analysis predicts outcomes as good as IPI, NCCN-IPI, and GELTAMO-IPI☆

弥漫大B细胞淋巴瘤中的实验室预后指数(LAB-PI):单一血液分析预测结果与IPI、NCCN-IPI和GELTAMO-IPI相当☆

2025-11-250
OAAI
Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

西班牙套细胞淋巴瘤(MCL)治疗模式与治疗顺序的演变及其对生存的影响:Geltamo-MCL-2022研究

BLOOD
IF23.1
2024-11-050
PRE
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment

大b细胞淋巴瘤患者在三线或更晚线治疗car-t进展后CAR预后指数的开发和验证

2024-10-290
OAAI
Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO

老年患者的Anti-CD19 car-t细胞治疗: 来自GETH-TC/GELTAMO的多中心真实世界经验

2024-10-012
PRE
Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy
2024-05-212
OAAI
New therapies for relapsed or refractory aggressive B-cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group
2024-04-220
OAAI
Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/ GETH Study

SCHOLAR-1标准对侵袭性B淋巴瘤嵌合抗原受体T细胞治疗疗效的影响: 一项真实世界的GELTAMO/ GETH研究

2023-12-010
OAAI
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial
2023-08-104
OAAI
Extranodal natural killer/T-cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets
2023-03-164
OA
Genetic Testing at Diagnosis Has Prognostic Value in Patients with Chronic Lymphocytic Leukemia including at Early Stages

诊断时的基因检测对包括早期在内的慢性淋巴细胞白血病患者具有预后价值

2022-07-250
OAAI
Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups

Car-t细胞时代难治性侵袭性b细胞淋巴瘤患者的最佳治疗选择: 来自GELTAMO/GETH西班牙小组的真实世界证据

2022-07-1229
OAAI
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
2022-06-3080
OAAI
RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group
2020-02-2024
PREAI